These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34996987)

  • 1. Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network.
    Gao Q; Zhang W; Li T; Yang G; Zhu W; Chen N; Jin H
    Sci Rep; 2022 Jan; 12(1):188. PubMed ID: 34996987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
    Krejner-Bienias A; Grzela K; Grzela T
    Arch Immunol Ther Exp (Warsz); 2021 Feb; 69(1):1. PubMed ID: 33527308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
    Mora-Rodríguez JM; Sánchez BG; Bort A; Díaz-Yuste A; Ballester-González R; Arrieta F; Sebastián-Martín A; Díaz-Laviada I
    Life Sci; 2024 Jan; 336():122292. PubMed ID: 38030058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
    Pitocco D; Tartaglione L; Viti L; Di Leo M; Pontecorvi A; Caputo S
    Diabetes Res Clin Pract; 2020 May; 163():108162. PubMed ID: 32335097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Interaction Map of Human SARS-CoV-2 Target Genes: Implications for Therapeutic Avenues.
    Subbarayan K; Ulagappan K; Wickenhauser C; Bachmann M; Seliger B
    Front Immunol; 2021; 12():597399. PubMed ID: 33796097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.
    Strollo R; Maddaloni E; Dauriz M; Pedone C; Buzzetti R; Pozzilli P
    Diabetes Res Clin Pract; 2021 Jan; 171():108444. PubMed ID: 32946854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications.
    Drucker DJ
    Endocr Rev; 2020 Jun; 41(3):. PubMed ID: 32294179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
    Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
    J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes.
    Shao S; Yang Q; Pan R; Yu X; Chen Y
    Front Endocrinol (Lausanne); 2021; 12():731974. PubMed ID: 34690930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview.
    Bernstein HG; Keilhoff G; Dobrowolny H; Steiner J
    Rev Neurosci; 2023 Jan; 34(1):1-24. PubMed ID: 35771831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
    Mulvihill EE; Drucker DJ
    Endocr Rev; 2014 Dec; 35(6):992-1019. PubMed ID: 25216328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring novel targets of sitagliptin for type 2 diabetes mellitus: Network pharmacology, molecular docking, molecular dynamics simulation, and SPR approaches.
    Qi JH; Chen PY; Cai DY; Wang Y; Wei YL; He SP; Zhou W
    Front Endocrinol (Lausanne); 2022; 13():1096655. PubMed ID: 36699034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
    Zhong J; Maiseyeu A; Davis SN; Rajagopalan S
    Circ Res; 2015 Apr; 116(8):1491-504. PubMed ID: 25858071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
    Solerte SB; Di Sabatino A; Galli M; Fiorina P
    Acta Diabetol; 2020 Jul; 57(7):779-783. PubMed ID: 32506195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
    Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
    Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 and diabetes: Can DPP4 inhibition play a role?
    Iacobellis G
    Diabetes Res Clin Pract; 2020 Apr; 162():108125. PubMed ID: 32224164
    [No Abstract]   [Full Text] [Related]  

  • 18. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
    Mulvihill EE
    Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence.
    Pala L; Rotella CM
    J Diabetes Res; 2013; 2013():590456. PubMed ID: 23853775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.
    Ling J; Cheng P; Ge L; Zhang DH; Shi AC; Tian JH; Chen YJ; Li XX; Zhang JY; Yang KH
    Acta Diabetol; 2019 Mar; 56(3):249-272. PubMed ID: 30242726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.